Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Equity Average (2021 - 2025)

Historic Equity Average for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $12.5 million.

  • InMed Pharmaceuticals' Equity Average rose 4217.56% to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year increase of 4217.56%. This contributed to the annual value of $11.3 million for FY2025, which is 631.47% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Equity Average of $12.5 million as of Q3 2025, which was up 4217.56% from $10.2 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Equity Average registered a high of $14.7 million during Q4 2021, and its lowest value of $1.3 million during Q3 2023.
  • Over the past 5 years, InMed Pharmaceuticals' median Equity Average value was $10.2 million (recorded in 2024), while the average stood at $9.7 million.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Equity Average crashed by 8749.59% in 2023, and later surged by 60080.0% in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Equity Average stood at $14.7 million in 2021, then fell by 13.77% to $12.7 million in 2022, then crashed by 87.4% to $1.6 million in 2023, then skyrocketed by 356.39% to $7.3 million in 2024, then soared by 71.67% to $12.5 million in 2025.
  • Its Equity Average stands at $12.5 million for Q3 2025, versus $10.2 million for Q2 2025 and $6.6 million for Q1 2025.